Q&A: Pfizer's Dominic Spinella on the Challenges of Using NGS in Clinical Trials

Pfizer's head of translational medicine for biotechnology and biotherapeutics said that while next-gen sequencing is a useful technology, it would not be adopted by pharma for companion diagnostics. Rather, he believes it will remain a tool that is primarily used early in the research and discovery phases of drug development.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.